ML-007

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ML-007 is a selective muscarinic acetylcholine M 1 and M 4 receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias. It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC). The drug is taken orally. It produces antipsychotic-like effects in rodents, including inhibition of amphetamine and phencyclidine (PCP)-induced hyperlocomotion and activity in the conditioned avoidance response test. These effects appear to dependent on activation of both muscarinic acetylcholine M 1 and M 4 receptors. The drug is approximately 10-fold more potent than xanomeline in these tests. As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias. It is under development by MapLight Therapeutics. The drug is a small molecule, but its chemical structure does not seem to have been disclosed.

ML-007 is a selective muscarinic acetylcholine M 1 and M 4 receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias. It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC). The drug is taken orally. It produces antipsychotic-like effects in rodents, including inhibition of amphetamine and phencyclidine (PCP)-induced hyperlocomotion and activity in the conditioned avoidance response test. These effects appear to dependent on activation of both muscarinic acetylcholine M 1 and M 4 receptors. The drug is approximately 10-fold more potent than xanomeline in these tests. As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias. It is under development by MapLight Therapeutics. The drug is a small molecule, but its chemical structure does not seem to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377181033 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.